The British Society for Rheumatology Guideline for the Management of Systemic Lupus Erythematosus in Adults

In 2017, the British Society for Rheumatology issued guidelines for the management of systemic lupus erythematosus (SLE) in adults, based on a comprehensive review of literature and expert consensus. The guidelines recommend a systematic approach to diagnosis, assessment, and monitoring of SLE, emphasizing the importance of regular clinical evaluations and laboratory testing to categorize disease activity and guide treatment strategies. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antimalarials like hydroxychloroquine, and various immunosuppressants such as azathioprine, mycophenolate mofetil, and cyclophosphamide, with the addition of biologics like rituximab and belimumab for patients unresponsive to other treatments. The guidelines also stress the need for personalized medicine, minimal use of steroids, and the management of comorbidities and drug toxicities. The recommendations are supported by different levels of evidence and grades of recommendation, with a call for more high-quality randomized controlled trials to further refine treatment approaches.